Clinical Case Debate: Neoadjuvant Checkpoint Inhibition Versus Standard Chemotherapy

Author(s):  
Marco Bandini ◽  
Giuseppe Basile ◽  
Andrea Gallina
2020 ◽  
Vol 25 (1) ◽  
pp. 42-46
Author(s):  
A. A. Meshcheryakov ◽  
T. E. Tikhomirova ◽  
L. A. Meshcheryakova

Gestational trophoblastic neoplasia is a rare malignancy. The main treatment approach is chemotherapy. Almost all patients can be cured if the diagnosis is established timely and adequate treatment is provided in specialized centers. In a small part of patients, the tumor progresses despite the use of all standard chemotherapy regimens. Treatment of such patients is difficult for all oncologists, including ones working in specialized centers for the treatment of gestational trophoblastic neoplasia. This article presents a clinical case of the successful treatment of a patient with multidrug resistant gestational trophoblastic neoplasia using GEMOX regimen.


2020 ◽  
Author(s):  
David Veríssimo ◽  
de Castro Matilde Jácome ◽  
Catarina Ivo ◽  
Vitória Duarte ◽  
Mafalda Marcelino ◽  
...  

2021 ◽  
Vol 16 (3) ◽  
pp. 67-71
Author(s):  
G. M. Teletaeva ◽  
E. A. Ulrikh ◽  
D. Kh. Latipova ◽  
A. I. Semenova ◽  
E. V. Levchenko ◽  
...  

Gestational trophoblastic disease is a rare tumor highly sensitive to systemic drug therapy. The standard regimens of chemotherapy of I and II lines for patients in the high-risk group for gestational trophoblastic disease are the EMA-CO, EMA-EP and TP/TE regimens, which have been demonstrated to be effective and require adherence to drug doses and intervals of administration. If these criteria are not met, the risk of developing resistance with an unfavorable outcome for patients is extremely high. The situation is extremely difficult when a patient has an absolute allergic intolerance to one of the components of standard regimens, which is presented in a clinical case.


1995 ◽  
Vol 22 ◽  
pp. 29-35
Author(s):  
Jennifer Gutierrez ◽  
Anthony Caruso

2015 ◽  
Vol 21 ◽  
pp. 108-109
Author(s):  
Ana Abaroa-Salvatierra ◽  
Arti Patel ◽  
Mrunalini Deshmukh
Keyword(s):  

2003 ◽  
Vol 19 (3) ◽  
pp. 164-174 ◽  
Author(s):  
Stephen N. Haynes ◽  
Andrew E. Williams

Summary: We review the rationale for behavioral clinical case formulations and emphasize the role of the functional analysis in the design of individualized treatments. Standardized treatments may not be optimally effective for clients who have multiple behavior problems. These problems can affect each other in complex ways and each behavior problem can be influenced by multiple, interacting causal variables. The mechanisms of action of standardized treatments may not always address the most important causal variables for a client's behavior problems. The functional analysis integrates judgments about the client's behavior problems, important causal variables, and functional relations among variables. The functional analysis aids treatment decisions by helping the clinician estimate the relative magnitude of effect of each causal variable on the client's behavior problems, so that the most effective treatments can be selected. The parameters of, and issues associated with, a functional analysis and Functional Analytic Clinical Case Models (FACCM) are illustrated with a clinical case. The task of selecting the best treatment for a client is complicated because treatments differ in their level of specificity and have unequally weighted mechanisms of action. Further, a treatment's mechanism of action is often unknown.


1995 ◽  
Author(s):  
George E. Abbott ◽  
◽  
Ray William London ◽  
Irving Kirsch

Sign in / Sign up

Export Citation Format

Share Document